Huminsulin Basal (Nph) (Insulin Human)

Huminsulin Basal (Nph) is indicated for the long‑term management of blood glucose in adults and children with diabetes mellitus, particularly when a basal insulin component is required.

• Provides intermediate‑acting insulin coverage to maintain basal glucose levels between meals and overnight.
• Used as part of a basal‑bolus regimen in combination with rapid‑acting insulin analogues.
• Suitable for patients with type 1 diabetes who need a stable background insulin.
• Can be employed in type 2 diabetes when oral agents are insufficient to achieve glycemic targets.
• May be prescribed when a once‑ or twice‑daily injection schedule aligns with patient lifestyle.

• Huminsulin Basal (Nph) contains recombinant human insulin that binds to insulin receptors on muscle, fat and liver cells. Receptor activation triggers autophosphorylation and initiates intracellular signaling cascades, notably the PI3‑K/Akt pathway, which promotes translocation of GLUT‑4 transporters to the cell surface and enhances glucose uptake. The resulting metabolic actions suppress hepatic glucose production and facilitate peripheral glucose utilization, thereby lowering circulating blood glucose concentrations.

Adverse reactions to Huminsulin Basal (Nph) are reported in clinical use and may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is reduced.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat.
• Transient weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Persistent edema or fluid retention.
• Unexplained hypokalemia or electrolyte disturbances.

When prescribing Huminsulin Basal (Nph), clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess renal and hepatic function, as impairment can alter insulin clearance.
• Review patient history for recurrent hypoglycemia or hypoglycemia unawareness.
• Adjust dose during periods of illness, surgery, or changes in physical activity.
• Counsel patients on proper injection technique and rotation of sites to prevent lipodystrophy.
• Monitor blood glucose regularly, especially when initiating therapy or modifying the regimen.
• Use caution in pregnant or breastfeeding women; benefits should outweigh potential risks.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.

Huminsulin Basal (Nph) may interact with other medicines or substances that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other insulin products without appropriate dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low blood glucose.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemic effects.
• Corticosteroids or other drugs that raise blood glucose, requiring possible insulin dose increase.
• Alcohol consumption, especially in excess, which can unpredictably affect glucose levels.
• Thyroid hormones or adrenergic agonists that may alter insulin sensitivity.